Shots:

• The companies collaborated to commercialize five of Alvotech’s proposed biosimilars in the Philippines. Prolia, Xgeva, Simponi & Eylea are among the biosimilars planned under this agreement. Additionally, 2 suggested biosimilars for immunology and oncology are also included
• The agreement enhances Multicare’s oncology, rheumatology, gastroenterology, and ophthalmology, a portfolio that consists of 3 biosimilar candidates & ~50 generic therapies
• Lupin’s subsidiary Multicare will file for marketing approval and will be responsible for the distribution & commercialization of the biosimilars. The reference products are used to treat diseases related to ophthalmology, cancer, immunology, and bone disease

Ref: Lupin | Image: Lupin